Tau protein in cerebrospinal fluid: A possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis

Neuroscience Letters

Volumn 363, Issue 1, 2004, Pages 14-17

  Martínez Yélamos, Antonio ^a   Saiz, Albert ^b   Bas, Jordi ^c   Hernandez, Juan Jose ^d   Graus, Francesc ^b   Arbizu, Txomin ^d  

^a HOSPITAL DE VILADECANS   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Axonal damage; Biochemical marker; Cerebrospinal fluid; Disability; Multiple sclerosis; Tau protein

Indexed keywords

BIOCHEMICAL MARKER; TAU PROTEIN;

ADULT; ARTICLE; AXONAL INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; QUESTIONNAIRE; RECURRENT DISEASE; REMISSION;

ADULT; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPINAL PUNCTURE; STATISTICS, NONPARAMETRIC; TAU PROTEINS; TIME FACTORS;

EID: 2442586536     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.03.039     Document Type: Article

References (10)

1. Binder L.I., Frankfurter A., Rebhun L.I. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 101:1985;1371-1378
2. Confavreux C., Compston D.A.S., Hommes O.R., McDonald W.I., Thompson A.J. EDMUS, a European database for multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 55:1992;671-676
3. Eikelenboom M.J., Petzold A., Lazeron R.H.C., Silber E., Sharief M., Thompson E.J., Barkhof F., Giovannoni G., Polman C.H., Uitdehaag B.M. Multiple sclerosis. Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology. 60:2003;219-223
4. Jimémez-Jimémez F.J., Zurdo J.M., Hernanz A., Medina-Acebron S., De Bustos F., Barcenilla B., Sayed Y., Ayuso-Peralta L. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol. Scand. 106:2002;351-354
5. Kapaki E., Paraskevas G.P., Michalopoulou M., Kilidireas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur. Neurol. 43:2000;228-232
6. Martínez-Yélamos A., Saiz A., Sanchez-Valle R., Casado V., Ramón J.M., Graus F., Arbizu T. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology. 57:2001;722-724
7. Otto M., Wiltfang J., Cepek L., Neumann M., Mollenhauer B., Steinacker P., Ciesielczyk B., Schulz-Schaeffer W., Kretzschmar H.A., Poser S. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 58:2002;192-197
8. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.S., Johnson K.P., Sibley W.A., Silberberg D.M., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis; guidelines for research protocols. Ann. Neurol. 13:1983;227-231
9. Sussmuth S.D., Reiber H., Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases. Neurosci. Lett. 300:2001;95-98
10. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:1998;278-285